NANOBX

Serial Number 99259194
630

Registration Progress

Application Filed
Jun 30, 2025
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

NANOBX

Basic Information

Serial Number
99259194
Filing Date
June 30, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
630
Status Date
Jun 30, 2025
Application
Pending
Classes
001 005

Rights Holder

Kaigene, Inc.

03
Address
9808 Medical Center Dr. Suite #430
Rockville, MD 20850

Ownership History

Kaigene, Inc.

Original Applicant
03
Rockville, MD

Legal Representation

Attorney
Devon E. White

Application History

2 events
Date Code Type Description
Jun 30, 2025 MAFR O APPLICATION FILING RECEIPT MAILED
Jun 30, 2025 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 001
Chemical preparations for scientific purposes; Molecules for use in industry, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for use in science, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for molecular biology, other than for medical or veterinary use, namely, protein-modulating molecules for use in the pharmaceutical industry
Class 005
Pharmaceutical and therapeutic preparations, namely, a drug formulation using protein degradation for use in treating immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Biochemical preparations for medical use for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical preparations for targeted protein degradation, comprising small molecules, peptides, biologics, antibodies designed for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Proteins, protein fragments, and protein conjugates all for use in the manufacture of pharmaceutical preparations for treatment of immunologic diseases, particularly autoimmune diseases

Classification

International Classes
001 005